http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
OSE Immunotherapeutics Announces Four Poster Presentations of Neoepitope Combination Tedopi® in Immuno-Oncology at ASCO 2022
-
OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression
-
OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression
-
OSE Immunotherapeutics To Present at ‘Immuno-Oncology Summit Europe’ and at ‘Tumor Myeloid-Directed Therapies Summit’ In London and Boston
-
OSE Immunotherapeutics To Present at ‘Immuno-Oncology Summit Europe’ and at ‘Tumor Myeloid-Directed Therapies Summit’ In London and Boston
-
Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncology
-
Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncolog
-
OSE Immunotherapeutics Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy
-
OSE Immunotherapeutics Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy
-
OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Cancer Immunotherapy
-
OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Cancer Immunotherapy
-
OSE Immunotherapeutics Reports 2021 Financial Results: Major Progress on its Clinical Programs and a Solid Cash Position to Support its Activities
-
OSE Immunotherapeutics Reports 2021 Financial Results: Major Progress on its Clinical Programs and a Solid Cash Position to Support its Activities
-
OSE Immunotherapeutics Receives First Notice of Allowance for a US Patent Covering Anti-PD1 Monoclonal Antibody OSE-279 And its Use in Cancer Treatment
-
OSE Immunotherapeutics Receives First Notice of Allowance for a US Patent Covering Anti-PD1 Monoclonal Antibody OSE-279 And its Use in Cancer Treatment
-
OSE Immunotherapeutics Provides Positive Long Term Memory Responses with CoVepiT, its T Lymphocyte Multi-Target Anti-COVID Vaccine
-
OSE Immunotherapeutics Provides Positive Long Term Memory Responses with CoVepiT, its T Lymphocyte Multi-Target Anti-COVID Vaccine
-
Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses from the Phase 1 Clinical Trial with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors
-
Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses From the Phase 1 Clinical Trial With First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors
-
OSE Immunotherapeutics Announces Appointment of Alexandre Lebeaut as an Independent Member of the Board of Directors
-
OSE Immunotherapeutics Announces Appointment of Alexandre Lebeaut as an Independent Member of the Board of Directors
-
OSE Immunotherapeutics is Pleased to Announce that Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, has Obtained FDA Fast-Track Designation for CD28 Antagonist VEL-101/FR104
-
OSE Immunotherapeutics is Pleased to Announce that Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, has Obtained FDA Fast-Track Designation for CD28 Antagonist VEL-101/FR104
-
Transfer of OSE Immunotherapeutics’ Shares from Compartment C to Compartment B of Euronext Paris from January 31, 2022
-
Transfer of OSE Immunotherapeutics’ Shares from Compartment C to Compartment B of Euronext Paris from January 31, 2022
-
OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, for CD28 Antagonist VEL-101/
-
OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, for CD28 Antagonist VEL-101
-
OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients
-
OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients
-
OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles
-
OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles
-
OSE Immunotherapeutics Strengthens Leadership Team with the Appointment of Laurence de Schoulepnikoff as Chief Business Officer
-
OSE Immunotherapeutics Strengthens Leadership Team with the Appointment of Laurence de Schoulepnikoff as Chief Business Officer
-
OSE Immunotherapeutics is Pleased to Announce the Continuation of its Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011 in Ulcerative Colitis after the Interim Futility Analysis
-
OSE Immunotherapeutics is Pleased to Announce the Continuation of its Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011 in Ulcerative Colitis after the Interim Futility Analysis
-
OSE Immunotherapeutics Presents First Preclinical Efficacy Data on Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia
-
OSE Immunotherapeutics Presents First Preclinical Efficacy Data on Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia
-
OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of CoVepiT, its Multi-Target T-cell Anti-COVID Vaccine
-
OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of CoVepiT, its Multi-Target T-cell Anti-COVID Vaccine
-
OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer
-
OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer
-
OSE Immunotherapeutics Presented New Translational Data on Tedopi® and Preclinical Data on PD-1/IL-7 Bifunctional Program BiCKI®-IL-7
-
OSE Immunotherapeutics Presented New Translational Data on Tedopi® and Preclinical Data on PD-1/IL-7 Bifunctional Program BiCKI®-IL-7
-
OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Data on CLEC-1, a Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy
-
OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Data on CLEC-1, a Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy
-
OSE Immunotherapeutics to Present New Preclinical Data at Upcoming Bispecific Antibody and Immunology Conferences
-
OSE Immunotherapeutics to Present New Preclinical Data at Upcoming Bispecific Antibody and Immunology Conferences
-
OSE Immunotherapeutics to Present New Clinical and Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
-
OSE Immunotherapeutics to Present New Clinical and Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
-
OSE Immunotherapeutics to Host Today a Virtual “Immuno-Oncology R&D Day”
